Incorporating Diagnostic Advances to Improve the Management of Alzheimer’s Disease
A CME-certified Program

Registration Statement

By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


View Agenda  The Pinehurst HotelVillage of Pinehurst, NC Saturday
Feb 22, 2014 4:30 PM

This program is part of a series of Topics in Neurology programs; Click Here for information.

Program Description

An advancing knowledge of the neuropathological processes leading to Alzheimer's disease (AD) is causing major shifts in how the condition is diagnosed and managed. Recent changes – including the development of new diagnostic categories aimed at an earlier diagnosis, the incorporation of biomarkers into clinical practice, and the approval of an amyloid imaging agent – are making AD management increasingly complex.

The push for earlier diagnosis presents many treatment challenges for practicing clinicians, as little is known about the efficacy of existing agents in these earlier clinical phases of disease. In addition, emerging agents are interfering with the deposition of proteins thought responsible for neuronal damage, as opposed to current agents which attempt to compensate for already damaged neurons. This program will address these changes in the diagnosis and treatment of AD, to ensure that clinicians continue to improve the care of their AD patients.

Target Audience

This activity is intended for neurologists, psychiatrists, geriatricians, primary care providers, and other clinicians involved in the care of older adults.

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Describe the new diagnostic categories of AD and the impact that these new categories have on diagnosis and treatment considerations
  • Develop plans to incorporate newer diagnostic tools and biomarker assessments into the earlier diagnosis and treatment of individuals with AD
  • Devise appropriate, evidence-based treatment plans for individuals across each diagnostic category of AD

Speaking Faculty / Steering Committee

Marwan Sabbagh, MD, FAAN
Banner Sun Health Research Institute
Research Professor of Neurology
University of Arizona College of Medicine-Phoenix
Sun City, AZ

Read Biography

Steering Committee

Sanjay Asthana, MD, FACP, FRCP(C)
Professor of Medicine
Duncan G. Ballantine Chair in Geriatrics
Chief, Division of Geriatrics
Director, NIA/NIH Wisconsin Alzheimer's Disease Research Center
Director, Madison VA GRECC
University of Wisconsin School of Medicine and Public Health
Madison, WI

Read Biography

R. Scott Turner, MD, PhD
Professor of Neurology
Director, Memory Disorders Program
Georgetown University Medical Center
Washington, DC

Read Biography


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit, the post-test, or evaluation, please email

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided upon submission of a completed evaluation form.

There is no fee associated with this program.


Event staff will be glad to assist you with any special needs. Please email at least 5 days prior to the program.

Jointly Sponsored By

Jointly sponsored by Potomac Center for Medical Education and Rockpointe

Supported By

This program is supported through an educational grant from Lilly USA, LLC and Novartis Pharmaceutical Corporation.

Registration Statement

By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.

Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.


View Agenda  The Pinehurst HotelVillage of Pinehurst, NC Saturday
Feb 22, 2014 4:30 PM